Author:
Minakata Daisuke,Fujiwara Shin-ichiro,Ikeda Takashi,Toda Yumiko,Ito Shoko,Mashima Kiyomi,Umino Kento,Nakano Hirofumi,Yamasaki Ryoko,Morita Kaoru,Kawasaki Yasufumi,Sugimoto Miyuki,Yamamoto Chihiro,Ashizawa Masahiro,Hatano Kaoru,Sato Kazuya,Oh Iekuni,Ohmine Ken,Muroi Kazuo,Kanda Yoshinobu
Publisher
Springer Science and Business Media LLC
Reference19 articles.
1. Dombret H, Gardin C. An update of current treatments for adult acute myeloid leukemia. Blood. 2016;127:53–61.
2. Burnett AK, Milligan D, Prentice AG, Goldstone AH, McMullin MF, Hills RK, et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer. 2007;109:1114–24.
3. Yamada K, Furusawa S, Saito K, Waga K, Koike T, Arimura H, et al. Concurrent use of granulocyte colony-stimulating factor with low-dose cytosine arabinoside and aclarubicin for previously treated acute myelogenous leukemia: a pilot study. Leukemia. 1995;9:10–4.
4. Zhu HH, Jiang H, Jiang B, Lu J, Jiang Q, Bao L, et al. Cytarabine, aclarubicin and granulocyte colony-stimulating factor regimen represents an effective and safe salvage regimen for patients with acute myeloid leukemia refractory to first course of induction chemotherapy. Leuk Lymphoma. 2013;54:2452–7.
5. Wei G, Ni W, Chiao JW, Cai Z, Huang H, Liu D. A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome. J Hematol Oncol. 2011;4:46–58.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献